Drug Combo Shows Benefits in Rare, Aggressive Kidney Cancer

(MedPage Today) — The combination of investigational sintilimab with axitinib (Inlyta) showed promise in patients with fumarate hydratase (FH)-deficient renal cell carcinoma (RCC), according to a phase II nonrandomized trial in China.
Among 41…